Latest Market Development News

NexGen Energy has expanded its Australian equity offering to AUD 600 million alongside a concurrent C$400 million North American deal, aiming to accelerate development of its flagship Rook I uranium project.

CONNEQT Health has raised $2 million through a convertible note facility with a director-owned entity, providing fresh capital to support its growth plans. Shareholder approval will be key to unlocking the full benefits of this funding.

Reef Casino Trust (ASX, RCT) has received a recommended off-market takeover offer from Iris Cairns Property Pty Ltd at $3.87 per unit, representing a significant premium over recent trading prices. The independent expert affirms the offer as fair and reasonable, with major unitholders supporting the bid subject to regulatory approvals.

Eagle Mountain Mining Limited has dismissed any undisclosed price-sensitive information following a sharp rise in its share price, attributing the movement to external market events and ongoing strategic negotiations.

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.

360 Capital Mortgage REIT (ASX – TCF) has announced a non-renounceable 1-for-1 entitlement offer to raise approximately $45.2 million, aiming to expand its senior loan investments secured by Australian real estate. The offer includes an oversubscription facility and a shortfall offer targeting wholesale and institutional investors.

Advanced Braking Technology (ABT) reported robust FY25 financial results marked by revenue growth and improved profitability, while advancing its strategic roadmap focused on mining safety innovations and global market expansion.

Eden Innovations Ltd reported a 21% revenue increase driven by global sales growth, yet its net loss widened significantly due to prior year asset revaluations and ongoing operational costs. The company is undertaking major financial restructuring including a share consolidation and rights issue to stabilize its balance sheet.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Seafarms Group Limited reported a reduced loss of $11.7 million for FY2025, despite a 43% drop in revenue and ongoing legal challenges surrounding Project Sea Dragon. Production setbacks from flooding and subdued market demand weighed heavily on results.

Linius Technologies reported a $5.31 million loss for FY25 as it shifts towards a sales-driven SaaS model, with new leadership and cost-cutting measures aiming to reshape its future.

Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.